(Q34065405)

English

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Stéphane Bretagne

object named as

S Bretagne

11

0 references

Philippe Ravaud

object named as

P Ravaud

3

0 references

author name string

F Tubach

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D Salmon

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Y Allanore

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

P Goupille

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Bréban

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B Pallot-Prades

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Pouplin

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Sacchi

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

R M Chichemanian

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D Emilie

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Lemann

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

O Lortholary

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

X Mariette

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Research Axed on Tolerance of Biotherapies Group

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1884-1894

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Biologics in the treatment of uveitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Infections and anti–tumor necrosis factor α therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Limitations and strengths of spontaneous reports data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

5 July 2018

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

1 reference

https://api.crossref.org/works/10.1002%2FART.24632

21 January 2018

Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor α

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921546

28 October 2018

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Failed validation of a clinical decision rule for the use of radiography in acute ankle injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The reporting sensitivities of two passive surveillance systems for vaccine adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19565495

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.24632

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34065405&oldid=1982974069"